======= ELAVL1 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: ELAVL1
  * **<color #00a2e8>Official Name</color>**: ELAV like RNA binding protein 1
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=1994|1994]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q15717|Q15717]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=ELAVL1&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ELAVL1|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/603466|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  RNA-binding protein that binds to the 3'-UTR region of mRNAs and increases their stability (PubMed:14517288, PubMed:18285462). Involved in embryonic stem cells (ESCs) differentiation: preferentially binds mRNAs that are not methylated by N6-methyladenosine (m6A), stabilizing them, promoting ESCs differentiation (By similarity). Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:8626503, PubMed:17632515, PubMed:18285462, PubMed:23519412). Binds avidly to the AU-rich element in FOS and IL3/interleukin-3 mRNAs. In the case of the FOS AU-rich element, binds to a core element of 27 nucleotides that contain AUUUA, AUUUUA, and AUUUUUA motifs. Binds preferentially to the 5'- UUUU[AG]UUU-3' motif in vitro (PubMed:8626503). With ZNF385A, binds the 3'-UTR of p53/TP53 mRNA to control their nuclear export induced by CDKN2A. Hence, may regulate p53/TP53 expression and mediate in part the CDKN2A anti-proliferative activity. May also bind with ZNF385A the CCNB1 mRNA (By similarity). {ECO:0000250|UniProtKB:P70372, ECO:0000269|PubMed:14517288, ECO:0000269|PubMed:17632515, ECO:0000269|PubMed:18285462, ECO:0000269|PubMed:19029303, ECO:0000269|PubMed:23519412, ECO:0000269|PubMed:8626503}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|RRM 1|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|AU-rich element binding|
|negative regulation of gene silencing by miRNA|
|negative regulation of gene silencing by RNA|
|negative regulation of posttranscriptional gene silencing|
|3-UTR-mediated mRNA stabilization|
|mRNA 3-UTR AU-rich region binding|
|regulation of stem cell population maintenance|
|miRNA binding|
|negative regulation of gene silencing|
|mRNA stabilization|
|RNA stabilization|
|negative regulation of mRNA catabolic process|
|negative regulation of RNA catabolic process|
|cytoplasmic stress granule|
|double-stranded RNA binding|
|mRNA 3-UTR binding|
|negative regulation of mRNA metabolic process|
|postsynapse|
|regulation of gene silencing by miRNA|
|regulation of posttranscriptional gene silencing|
|regulation of gene silencing by RNA|
|positive regulation of translation|
|regulation of gene silencing|
|positive regulation of cellular amide metabolic process|
|ribonucleoprotein complex|
|mRNA binding|
|regulation of mRNA stability|
|regulation of RNA stability|
|regulation of mRNA catabolic process|
|negative regulation of cellular catabolic process|
|mRNA splicing, via spliceosome|
|RNA splicing, via transesterification reactions with bulged adenosine as nucleophile|
|RNA splicing, via transesterification reactions|
|negative regulation of catabolic process|
|regulation of mRNA metabolic process|
|protein homooligomerization|
|glutamatergic synapse|
|regulation of translation|
|RNA splicing|
|regulation of cellular amide metabolic process|
|protein kinase binding|
|mRNA processing|
|protein complex oligomerization|
|posttranscriptional regulation of gene expression|
|mRNA metabolic process|
|regulation of cellular catabolic process|
|RNA processing|
|protein homodimerization activity|
|regulation of catabolic process|
|negative regulation of RNA metabolic process|
|RNA binding|
|negative regulation of nucleobase-containing compound metabolic process|
|protein-containing complex assembly|
|positive regulation of cellular protein metabolic process|
|RNA metabolic process|
|positive regulation of protein metabolic process|
|protein-containing complex subunit organization|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|membrane|
|gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-2.98|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-2.9|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|-2.84|
|[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|-2.79|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.77|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-2.74|
|[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|-2.68|
|[[:results:exp382|Palbociclib 1μM R07 exp382]]|-2.65|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-2.64|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|-2.6|
|[[:results:exp125|GSK461364A 0.005μM R03 exp125]]|-2.53|
|[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|-2.51|
|[[:results:exp122|Golgicide-A 4μM R03 exp122]]|-2.49|
|[[:results:exp162|BI-D1870 2μM R04 exp162]]|-2.47|
|[[:results:exp241|QNZ 0.01μM R05 exp241]]|-2.35|
|[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|-2.31|
|[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|-2.3|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-2.12|
|[[:results:exp155|UNC1999 2μM R03 exp155]]|-2.11|
|[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|-2.08|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|-2.08|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-2.06|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-2.02|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-2.02|
|[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|-1.96|
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-1.96|
|[[:results:exp233|EPZ-5676 30μM R05 exp233]]|-1.86|
|[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-1.85|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-1.84|
|[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|-1.76|
|[[:results:exp83|Trametinib 10μM R02 exp83]]|-1.75|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|-1.74|
|[[:results:exp291|LLY-284 2.6μM R06 exp291]]|-1.73|
|[[:results:exp274|Citral 50μM R06 exp274]]|1.77|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|1.87|
|[[:results:exp343|Centrinone 0.5μM R07 exp343]]|1.88|
|[[:results:exp441|GSK-J4 1.5μM R08 exp441]]|1.88|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|1.93|
|[[:results:exp70|INK128 0.2μM R02 exp70]]|1.94|
|[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|2.01|
|[[:results:exp512|Olaparib 4μM R08 exp512]]|2.09|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|2.13|
|[[:results:exp363|GSK-J4 1-1.25μM to day4 R07 exp363]]|2.14|
|[[:results:exp525|Sulforaphane 9μM R08 exp525]]|2.57|
|[[:results:exp414|Tozasertib 0.1μM R07 exp414]]|3.01|
|[[:results:exp349|Cytochalasin-B 5μM R07 exp349]]|3.37|
|[[:results:exp256|HMS-I1 10μM R06 exp256]]|3.65|
|[[:results:exp374|Latrunculin-B 10μM R07 exp374]]|3.71|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|6.43|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|8|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:h:hnrnpl|HNRNPL]]|0.441|
|[[:human genes:c:casp3|CASP3]]|0.436|
|[[:human genes:t:tnfrsf10b|TNFRSF10B]]|0.435|
|[[:human genes:c:casp8|CASP8]]|0.425|
|[[:human genes:c:cxorf38|CXorf38]]|0.417|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 2/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|1/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 18613
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.27 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='ELAVL1 Expression in NALM6 Cells: 7.27'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>